Glanzmann's thrombasthenia historical perspective: Difference between revisions
No edit summary |
m (Bot: Removing from Primary care) |
||
| (8 intermediate revisions by one other user not shown) | |||
| Line 2: | Line 2: | ||
{{Glanzmann's thrombasthenia}} | {{Glanzmann's thrombasthenia}} | ||
{{CMG}} | {{CMG}} {{AE}} {{OK}}, [[User:Niush.D|Niyousha Danesh, MD-MPH]] | ||
==Overview== | ==Overview== | ||
In 1918, Eduard Glanzmann, a Swiss [[pediatrician]], described [[Glanzmann's thrombasthenia]] for the first time. It was known formerly as “[[hereditary]] [[hemorrhagic]] [[thrombasthenia]]”, but Glanzmann proposed it was not abnormal [[platelet]] number but a disorder of [[clotting]]. Later, it was defined as a heritable platelet disorder secondary to a dysfunction in [[GPIIb/IIIa]] complex. In 1956, Braunsteiner and Pakesch described [[Glanzmann's thrombasthenia]] as an inherited disorder with normal sized platelets that failed [[clot retraction]]. In 1965, Castaldi and Caen 7 showed that the [[platelet]] [[fibrinogen]] was either strongly diminished (in parallel with the impaired [[clot retraction]]) or borderline to the normal range. In 1966, Caen et al. explained 15 patients with [[Glanzmann's thrombasthenia]], with decreased or nil [[platelet aggregation]] but the [[clot retraction]] was sometimes only mildly effected. The variant disease was first established in 1987 In the mid 1970’s, Nurden and Caen and Phillips et al. discovered a deficiency of both [[Glycoprotein IIb/IIIa|GPIIb/GPIIIa]] in thrombasthenic [[platelets]]. Today, it receives much recognition, as it was one of the first disorders to define [[GPIIb/IIIa]] as a platelet receptor for adhesive molecules (such as [[Von Willebrand factor|VWF]] and [[fibrinogen]]). Glanzmann's thrombasthenia served as a template for platelet aggregation process as well as targets for therapeutic measures. | |||
==Historical Perspective== | ==Historical Perspective== | ||
In 1918, Eduard Glanzmann, a Swiss [[pediatrician]], first | In 1918, Eduard Glanzmann, a Swiss [[pediatrician]], described [[Glanzmann's thrombasthenia]] for the first time. It was known formerly as “[[hereditary]] [[hemorrhagic]] [[thrombasthenia]]”, but Glanzmann proposed it was not abnormal [[platelet]] number but a disorder of [[clotting]]<ref name="pmid26185478">{{cite journal |vauthors=Solh T, Botsford A, Solh M |title=Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options |journal=J Blood Med |volume=6 |issue= |pages=219–27 |date=2015 |pmid=26185478 |pmc=4501245 |doi=10.2147/JBM.S71319 |url=}}</ref>. Later, it was defined as a heritable platelet disorder secondary to a dysfunction in [[GPIIb/IIIa]] complex.<ref name="pmid26185478">{{cite journal| author=Solh T, Botsford A, Solh M| title=Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options. | journal=J Blood Med | year= 2015 | volume= 6 | issue= | pages= 219-27 | pmid=26185478 | doi=10.2147/JBM.S71319 | pmc=4501245 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26185478 }}</ref> | ||
In 1956, Braunsteiner and Pakesch described [[Glanzmann's thrombasthenia]] as an inherited disorder with normal sized platelets that failed [[clot retraction]].<ref name="pmid16722529">{{cite journal |vauthors=Nurden AT |title=Glanzmann thrombasthenia |journal=Orphanet J Rare Dis |volume=1 |issue= |pages=10 |date=April 2006 |pmid=16722529 |pmc=1475837 |doi=10.1186/1750-1172-1-10 |url=}}</ref> | |||
In | In 1965, Castaldi and Caen 7 showed that the [[platelet]] [[fibrinogen]] was either strongly diminished (in parallel with the impaired [[clot retraction]]) or borderline to the normal range. In the mid 1970’s, Nurden and Caen and Phillips et al. discovered a deficiency of both [[Glycoprotein IIb/IIIa|GPIIb/GPIIIa]] in thrombasthenic [[platelets]].<ref name="pmid12487785">{{cite journal| author=Nair S, Ghosh K, Kulkarni B, Shetty S, Mohanty D| title=Glanzmann's thrombasthenia: updated. | journal=Platelets | year= 2002 | volume= 13 | issue= 7 | pages= 387-93 | pmid=12487785 | doi=10.1080/0953710021000024394 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12487785 }}</ref> | ||
In 1966, Caen et al. explained 15 patients with [[Glanzmann's thrombasthenia]], with decreased or nil [[platelet aggregation]] but the [[clot retraction]] was sometimes only mildly effected.<ref name="pmid16722529">{{cite journal |vauthors=Nurden AT |title=Glanzmann thrombasthenia |journal=Orphanet J Rare Dis |volume=1 |issue= |pages=10 |date=April 2006 |pmid=16722529 |pmc=1475837 |doi=10.1186/1750-1172-1-10 |url=}}</ref>The variant disease was first established in 1987.<ref name="pmid16722529" /> | |||
Today, it receives much recognition, as it was one of the first disorders to define [[GPIIb/IIIa]] as a platelet receptor for adhesive molecules (such as [[Von Willebrand factor|VWF]] and [[fibrinogen]]). Glanzmann's thrombasthenia served as a template for platelet aggregation process as well as targets for therapeutic measures.<ref name="pmid26185478" /> | |||
==References== | ==References== | ||
| Line 30: | Line 23: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
Latest revision as of 21:52, 29 July 2020
|
Glanzmann's thrombasthenia |
|
Differentiating Glanzmann's thrombasthenia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Glanzmann's thrombasthenia historical perspective On the Web |
|
American Roentgen Ray Society Images of Glanzmann's thrombasthenia historical perspective |
|
Glanzmann's thrombasthenia historical perspective in the news |
|
Risk calculators and risk factors for Glanzmann's thrombasthenia historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Omer Kamal, M.D.[2], Niyousha Danesh, MD-MPH
Overview
In 1918, Eduard Glanzmann, a Swiss pediatrician, described Glanzmann's thrombasthenia for the first time. It was known formerly as “hereditary hemorrhagic thrombasthenia”, but Glanzmann proposed it was not abnormal platelet number but a disorder of clotting. Later, it was defined as a heritable platelet disorder secondary to a dysfunction in GPIIb/IIIa complex. In 1956, Braunsteiner and Pakesch described Glanzmann's thrombasthenia as an inherited disorder with normal sized platelets that failed clot retraction. In 1965, Castaldi and Caen 7 showed that the platelet fibrinogen was either strongly diminished (in parallel with the impaired clot retraction) or borderline to the normal range. In 1966, Caen et al. explained 15 patients with Glanzmann's thrombasthenia, with decreased or nil platelet aggregation but the clot retraction was sometimes only mildly effected. The variant disease was first established in 1987 In the mid 1970’s, Nurden and Caen and Phillips et al. discovered a deficiency of both GPIIb/GPIIIa in thrombasthenic platelets. Today, it receives much recognition, as it was one of the first disorders to define GPIIb/IIIa as a platelet receptor for adhesive molecules (such as VWF and fibrinogen). Glanzmann's thrombasthenia served as a template for platelet aggregation process as well as targets for therapeutic measures.
Historical Perspective
In 1918, Eduard Glanzmann, a Swiss pediatrician, described Glanzmann's thrombasthenia for the first time. It was known formerly as “hereditary hemorrhagic thrombasthenia”, but Glanzmann proposed it was not abnormal platelet number but a disorder of clotting[1]. Later, it was defined as a heritable platelet disorder secondary to a dysfunction in GPIIb/IIIa complex.[1]
In 1956, Braunsteiner and Pakesch described Glanzmann's thrombasthenia as an inherited disorder with normal sized platelets that failed clot retraction.[2]
In 1965, Castaldi and Caen 7 showed that the platelet fibrinogen was either strongly diminished (in parallel with the impaired clot retraction) or borderline to the normal range. In the mid 1970’s, Nurden and Caen and Phillips et al. discovered a deficiency of both GPIIb/GPIIIa in thrombasthenic platelets.[3]
In 1966, Caen et al. explained 15 patients with Glanzmann's thrombasthenia, with decreased or nil platelet aggregation but the clot retraction was sometimes only mildly effected.[2]The variant disease was first established in 1987.[2]
Today, it receives much recognition, as it was one of the first disorders to define GPIIb/IIIa as a platelet receptor for adhesive molecules (such as VWF and fibrinogen). Glanzmann's thrombasthenia served as a template for platelet aggregation process as well as targets for therapeutic measures.[1]
References
- ↑ 1.0 1.1 1.2 Solh T, Botsford A, Solh M (2015). "Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options". J Blood Med. 6: 219–27. doi:10.2147/JBM.S71319. PMC 4501245. PMID 26185478.
- ↑ 2.0 2.1 2.2 Nurden AT (April 2006). "Glanzmann thrombasthenia". Orphanet J Rare Dis. 1: 10. doi:10.1186/1750-1172-1-10. PMC 1475837. PMID 16722529.
- ↑ Nair S, Ghosh K, Kulkarni B, Shetty S, Mohanty D (2002). "Glanzmann's thrombasthenia: updated". Platelets. 13 (7): 387–93. doi:10.1080/0953710021000024394. PMID 12487785.